ACH
Accendra Health Inc/Va/Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adj. EBITDA, Non-GAAP non-GAAP | $58.4M | 1Q26 | — |
| Adj. net (loss) income from continuing operations per share, Non-GAAP non-GAAP | -$0.04 | 1Q26 | — |
| Adj. net (loss) income from continuing operations, Non-GAAP non-GAAP | -$3.1M | 1Q26 | — |
| Operating cash flow | $154M | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Distribution — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACH
this stock
Accendra Health Inc/Va/
|
$252.73M | +13.2% | +3.1% | — | 8.7% |
|
MCK
Mckesson Corp
|
$95.30B | -0.1% | +3.1% | 20.7 | 3.7% |
|
COR
Cencora, Inc.
|
$58.85B | -8.2% | +9.3% | 23.2 | 3.2% |
|
CAH
Cardinal Health Inc
|
$55.01B | +16.0% | -1.9% | — | 3.8% |
|
HSIC
Henry Schein Inc
|
$9.55B | +10.1% | +5.9% | 25.3 | 6.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACH | -7.3% | +24.3% | +26.3% | -7.3% | +13.2% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -7.1% | +23.5% | +18.9% | -7.1% | +3.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.